In the premarket trading session, at last check, Atossa Therapeutics Inc. (ATOS) stock had surged by 2.55% to $6.04. ATOS’s stock previously closed the session gaining 10.09% to $5.89. The ATOS stock volume traded 14.72 million shares. In the past week, ATOS shares have moved up by 27.49%. In the past three and six months, the ATOS stock has jumped up by 135.60%, and 584.72% respectively. Furthermore, Atossa therapeutics Inc. is currently valued in the market at $711.65 million and has 120.82 million outstanding shares.
Here’s what you need to know about Atossa Therapeutics Inc.
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on the developing and designing of unique innovative treatments and medicines for the unmet needs of the health market. The company specifically focuses on the platform of development and design of medicines for the areas of oncology and infectious disease.
The company has created programs to fight breast cancers, improve lung functions and has therapy programs as well for the treatment of cancers. The lead candidate program is known as Endoxifen for breast cancer treatment which is in Phase II of clinical trials and is a metabolite of tamoxifen. AT-H201 and AT-301 are proprietary drugs used for the treatment and recovery of lung function in COVID19 patients. ATOS stock also participates and supports research for treatments like potential treatment of breast cancer through cytokine-coated nanoparticles in partnership with Dana-Farber Cancer Institute Inc. Furthermore, the company was previously known as Atossa Genetics Inc up till January 2020 and is founded in 2008. The Atossa headquarters is in Seattle Washington.
How has Atossa’s operations been doing lately?
The month of June has been very progressive and successful for ATOS stock and Atossa’s clinical study operations. On 16th June 2021, the company was announced to be part of the Russell 2000 and Russell 3000 Indexes. Atossa is primarily focusing on Breast cancer and COVID19-related treatments. There is a preliminary list of additions that were posted on 4th and 14th June 2021, informing that the official integration will be concluded on 2021 Russell Indexes’ annual reconstitution. The implementation will be effective after US market opens on June 28, 2021.
On 11th June 2021, ATOS stock received approval from the Swedish Medical Product Agency (MPA) which encourages the initiation of Endoxifen’s second phase clinical trial study. Endoxifen will be used for the treatment and reduction of mammographic breast density (MBD) which is affecting more than 10 million women in the US and scattered across the globe. Increased mammographic breast density results in the difficulty of detecting cancer and increases the development of breast cancer risk.
Furthermore, Atossa Therapeutics announced the final data of the phase 2 study of oral Endoxifen. This study was used to test the efficacy and safety of the administration of the dose between the time of diagnosis of breast cancer and surgery. The primary endpoint met result showed Ki-67 reduction by an average of 25.6% and has shown clinically meaningful results because these statistics according to to other studies showed a result of improved survival rate.
